Benefits of Switch from Oral to Subcutaneous Route on Adherence to Methotrexate in Patients with Rheumatoid Arthritis in Real Life Setting [Corrigendum]

Benefits of Switch from Oral to Subcutaneous Route on Adherence to Methotrexate in Patients with Rheumatoid Arthritis in Real Life Setting [Corrigendum]

Senbel E, Tropé S, Herman-Demars H, et al. Patient Prefer Adherence. 2021;15:751-760. Page 751, Abstract, Results section, the text "Switch to SC route increased the proportion of patients with remission or LDA from 22.8% to 52.9% and increased quality of life even in patients with unchanged MT...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Patient preference and adherence 2021-07, Vol.15, p.1679-1680
Hauptverfasser: Senbel, Eric, Tropé, Sonia, Herman-Demars, Hélène, Zinovieva, Elena, Courbeyrette, Agnès, Clerson, Pierre, Fardini, Yann, Flipo, René-Marc
Format: Artikel
Sprache:eng
Schlagworte:
compliance
Corrigendum
methotrexate
oral
rheumatoid arthritis
subcutaneous
switch
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Senbel E, Tropé S, Herman-Demars H, et al. Patient Prefer Adherence. 2021;15:751-760. Page 751, Abstract, Results section, the text "Switch to SC route increased the proportion of patients with remission or LDA from 22.8% to 52.9% and increased quality of life even in patients with unchanged MTX dose" should read "Switch to SC route increased the proportion of patients with remission or LDA from 22.2% to 52.3% and increased quality of life even in patients with unchanged MTX dose". The authors apologize for this error. Read the original article
ISSN:1177-889X
1177-889X
DOI:10.2147/PPA.S330289